推薦產品
等級
pharmaceutical primary standard
API 家族
capecitabine
製造商／商標名
EDQM
應用
pharmaceutical (small molecule)
格式
neat
儲存溫度
2-8°C
SMILES 字串
O[C@H]1[C@@H](O)[C@H](N2C(N=C(NC(OCCCCC)=O)C(F)=C2)=O)O[C@@H]1C
InChI
1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1
InChI 密鑰
GAGWJHPBXLXJQN-UORFTKCHSA-N
基因資訊
human ... TYMS(7298)
尋找類似的產品？ 前往 產品比較指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Capecitabine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化／生理作用
卡培他滨是一种抗癌药物，是去氧氟尿苷的前药，在肿瘤部位代谢为5-氟尿嘧啶。 卡培他滨的激活遵循具有三个酶促步骤和两个中间代谢物5′-脱氧-5-氟胞苷（5′-DFCR）和5′-脱氧-5-氟尿苷（5′-DFUR）的途径，形成5-氟尿嘧啶。
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
相關產品
產品號碼
描述
訂價
訊號詞
Danger
危險聲明
危險分類
Carc. 1B - Muta. 2 - Repr. 1B
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
客戶也查看了
Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.
Tim Meyer et al.
European journal of cancer (Oxford, England : 1990), 50(5), 902-911 (2014-01-22)
Cytotoxic chemotherapy is widely used for advanced, unresectable pancreatic and other gastrointestinal foregut neuroendocrine tumours (NETs) and the most commonly used regimen combines 5-fluorouracil with streptozocin. The NET01 trial was designed to investigate whether capecitabine combined with streptozocin was an
A Iu Abrosimov et al.
Arkhiv patologii, 75(6), 27-31 (2014-03-15)
The pathomorphism of rectal cancer (RC) was studied in 99 patients who received neoadjuvant chemoradiotherapy using two drugs (5-fluorouracil and xeloda). A morphological study indicated the qualitatively similar manifestations of pathomorphism (tumor necrosis, inflammation, and sclerosis) which were more pronounced
Mitsuhiro Tomoda et al.
Anticancer research, 34(1), 191-194 (2014-01-10)
Unresectable metastatic colorectal cancer with very slow tumour growth rate does not necessarily require for strong short-interval chemotherapy. In the present study, we administered monthly chemotherapy and aimed to evaluate the usefulness of the specific treatment schedule in patients with
Nestor F Esnaola et al.
International journal of radiation oncology, biology, physics, 88(4), 837-844 (2014-03-13)
To evaluate, in a phase 2 study, the safety and efficacy of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer (BRPC or LAPC, respectively). Patients received gemcitabine
Takahiro Yamanashi et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 41(1), 107-112 (2014-01-16)
A 77-year-old man who complained of melena was admitted to our department. Colonoscopy revealed a type 2 tumor in the hepatic flexure of the ascending colon. Biopsy examination revealed a poorly differentiated adenocarcinoma. Abdominal computed tomography(CT)revealed 3 tumors within the
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務